News Releases

Date	Title and Summary	View
Dec 14, 2018	Statement on Reuters Talc Article NEW BRUNSWICK, N.J. , Dec. 14, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today issued the following statement regarding speculation about the safety of our products. The Reuters article is one-sided, false, and inflammatory. Johnson & Johnson's baby powder is safe and asbestos-free.
Dec 12, 2018	New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48 84.5 percent of patients receiving TREMFYA achieved the primary endpoint of a PASI 90 response at week 48 compared with 70.0 percent of patients receiving Cosentyx ECLIPSE is the first Phase 3 head-to-head study to compare efficacy between the first-in-class IL-23 inhibitor, TREMFYA, and the IL-17
Dec 04, 2018	New DARZALEX® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of AntiCD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma
Dec 03, 2018	IMBRUVICA® (ibrutinib) Plus Obinutuzumab Showed Significant Improvement in Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dec 03, 2018	Updated Data from Phase 1/2 Open-Label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Tolerable Safety Profile, High Overall Response and MRD Negative Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myeloma
Dec 03, 2018	Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab
Nov 26, 2018	Johnson & Johnson to Participate in the BMO Prescriptions for Success Healthcare Conference NEW BRUNSWICK, N.J. , Nov. 26, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the BMO Prescriptions for Success Healthcare Conference on Wednesday, December 12 th , at The Mandarin Oriental, New York. Ciro Römer, Company Group Chairman for the Johnson & Johnson Medical
Nov 16, 2018	Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease
Nov 15, 2018	Janssen seeks expanded use of IMBRUVICA®▼ (ibrutinib) in two indications in Europe
Nov 12, 2018	Johnson & Johnson to Participate in the Citi's 2018 Global Healthcare Conference NEW BRUNSWICK, N.J. , Nov. 12, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Citi's 2018 Global Healthcare Conference on Wednesday, December 5 th , at the Lotte New York Palace Hotel in New York City. Joseph J. Wolk , Executive Vice President and Chief Financial